Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 237

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 237
---
 compensation allocated to directors in respect of 2024 represented 82.26% of their total compensation.

| 136 | SANOFIFORM 20-F2024 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

Compensation and benefits of all kinds paid during 2024 or awarded in respect of 2024 to Frédéric Oudéa, Chairman of the Board of Directors Frédéric Oudéa was appointed Chairman of the Board of Directors on May 25, 2023. He does not have a contract of employment with Sanofi. As Chairman of the Board, Frédéric Oudéa is a member of the Appointments, Governance and CSR Committee and the Scientific Committee, and Chair of the Strategy Committee. The remit of the Chairman of the Board is specified in the Board Charter, which is reproduced in its entirety in Exhibit 1.2. to this annual report. During 2024, the activities of Frédéric Oudéa as Chairman of the Board of Directors included: • chairing meetings of the Board of Directors (twelve meetings), attending meetings of Committees of which he is a member (six meetings of the Appointments, Governance and CSR Committee, five meetings of the Strategy Committee, and six meetings of the Scientific Committee), attending Committee meetings to which he was invited (Audit Committee and Compensation Committee), and attending the R&D pipeline review week; • organizing and chairing the strategy seminars held in April and October 2024, and organizing meetings and visits in China in December 2024; • monitoring of the proper implementation of the decisions taken by the Board; • meetings with directors, including (i) in connection with the evaluation of the Board’s operating procedures, (ii) on matters relating to the projects presented to the Board, and (iii) on corporate governance matters; • regular meetings with the members of the Executive Committee; • meetings with Sanofi employees and visits to subsidiaries of Sanofi; • meetings with biotech and medtech companies; and • representing Sanofi at events or official meetings (in France and abroad) with representatives of the public authorities and other stakeholders, in line with his remit as defined by the Board Charter, and in particular with the French State in respect of the proposed separation of Sanofi's Consumer Healthcare business. The Chairman also has a role in explaining positions taken by the Board within its sphere of competence, especially in terms of strategy, governance and executive compensation. In furtherance of this role